NeuroPace, Inc. (NASDAQ:NPCE) Receives $17.33 Average Price Target from Analysts

NeuroPace, Inc. (NASDAQ:NPCE) has received an average rating of “Moderate Buy” from the eight analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and six have issued a buy recommendation on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.3333.

A number of brokerages have recently issued reports on NPCE. Leerink Partners reiterated an “outperform” rating and set a $19.00 target price on shares of NeuroPace in a report on Wednesday, November 5th. Wells Fargo & Company lifted their price target on shares of NeuroPace from $15.00 to $16.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. JPMorgan Chase & Co. increased their price objective on shares of NeuroPace from $16.00 to $18.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 5th. Zacks Research downgraded shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 13th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research report on Wednesday, November 5th.

Institutional Investors Weigh In On NeuroPace

Several hedge funds have recently modified their holdings of NPCE. First Light Asset Management LLC purchased a new position in NeuroPace in the 1st quarter worth approximately $19,468,000. Driehaus Capital Management LLC purchased a new position in shares of NeuroPace in the first quarter valued at $9,874,000. Armistice Capital LLC boosted its stake in shares of NeuroPace by 94.7% in the first quarter. Armistice Capital LLC now owns 1,153,614 shares of the company’s stock valued at $14,178,000 after purchasing an additional 561,000 shares during the period. Deutsche Bank AG grew its holdings in NeuroPace by 124.0% during the 1st quarter. Deutsche Bank AG now owns 924,274 shares of the company’s stock valued at $11,359,000 after purchasing an additional 511,662 shares in the last quarter. Finally, Lord Abbett & CO. LLC purchased a new stake in NeuroPace during the 1st quarter worth $5,727,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

NeuroPace Trading Down 0.4%

Shares of NeuroPace stock opened at $16.43 on Thursday. The company has a debt-to-equity ratio of 3.17, a quick ratio of 3.94 and a current ratio of 4.86. The company has a market cap of $547.28 million, a P/E ratio of -21.62 and a beta of 1.90. NeuroPace has a fifty-two week low of $7.56 and a fifty-two week high of $18.98. The firm has a 50-day simple moving average of $11.78 and a two-hundred day simple moving average of $11.13.

NeuroPace (NASDAQ:NPCE) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. NeuroPace had a negative return on equity of 136.60% and a negative net margin of 25.28%.The business had revenue of $27.35 million during the quarter, compared to the consensus estimate of $24.64 million. NeuroPace has set its FY 2025 guidance at EPS. As a group, equities analysts predict that NeuroPace will post -1 earnings per share for the current fiscal year.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.